Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07288567 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

A Phase 3 study of Schizophrenia, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 3
Development phase
166
Enrollment target
20
Study locations

NCT07288567 is a Phase 3 study of Schizophrenia that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 166 participants, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07288567, a Phase 3 study of Schizophrenia, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 3
Development phase
166 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

Conditions Studied

Schizophrenia

Interventions

  • DRUG KarXT
  • OTHER KarXT Matching Placebo

Study Locations (20)

California

  • Local Institution - 0077 - Anaheim
  • Local Institution - 0058 - Chino
  • Local Institution - 0083 - Redlands
  • Local Institution - 0089 - San Francisco

Georgia

  • Atlanta Center for Medical Research - Atlanta
  • Local Institution - 0106 - Lawrenceville
  • Local Institution - 0039 - Stone Mountain

Massachusetts

  • Local Institution - 0076 - Boston
  • Local Institution - 0100 - Brookline
  • Local Institution - 0059 - Worcester

Texas

  • Local Institution - 0046 - Garland
  • Local Institution - 0090 - McAllen
  • Local Institution - 0066 - Spring

Illinois

  • Local Institution - 0044 - Chicago
  • Local Institution - 0107 - Evanston

Florida

  • Local Institution - 0032 - Orlando

Michigan

  • Local Institution - 0049 - Highland Park

New York

  • Local Institution - 0061 - Great Neck

Trial Details

FieldValue
Enrollment Target 166 participants
Start Date 2026-01-29
Est. Completion 2029-12-18
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07288567

The ClinicalTrials.gov registry entry for NCT07288567 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (24% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which KarXT is the first listed.

NCT07288567 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Georgia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07288567 about?

NCT07288567 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)". The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

What is the current status of trial NCT07288567?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 166 participants. The study started on 2026-01-29. Estimated completion is 2029-12-18.

What conditions does trial NCT07288567 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT07288567?

The interventions under investigation include: KarXT (DRUG), KarXT Matching Placebo (OTHER).

Who is sponsoring clinical trial NCT07288567?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07288567 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.